Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adherence, HIV-1 Infection, Resistance, and Renal and Skeletal Adverse Event in Individuals Taking Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF, Truvada®) for HIV Pre-Exposure Prophylaxis (PrEP): A Pooled Observational Study

NCT01906255 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT01906255
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01906255 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adherence, HIV-1 Infection, Resistance, and Renal and Skeletal Adverse Event in Individuals Taking Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF, Truvada®) for HIV Pre-Exposure Prophylaxis (PrEP): A Pooled Observational Study
Lead sponsor
Gilead Sciences
Phase
Observational
Overall status
Completed
Start date
October 7, 2013
Completion date
April 27, 2021
Enrollment
10,577 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv